Kossan Rubber Industries Bhd (KSRBF)
USD 0.27
(0.0%)
USD 0.27
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 386.76 Million MYR | -9.89% |
| 2022 | 429.21 Million MYR | -57.9% |
| 2021 | 1.01 Billion MYR | -16.49% |
| 2020 | 1.22 Billion MYR | 31.8% |
| 2019 | 926.23 Million MYR | 14.94% |
| 2018 | 805.85 Million MYR | 17.34% |
| 2017 | 686.79 Million MYR | 43.77% |
| 2016 | 477.7 Million MYR | -4.43% |
| 2015 | 499.84 Million MYR | 8.27% |
| 2014 | 461.65 Million MYR | 20.22% |
| 2013 | 384 Million MYR | 3.08% |
| 2012 | 372.54 Million MYR | 21.7% |
| 2011 | 306.11 Million MYR | -8.0% |
| 2010 | 332.72 Million MYR | 0.97% |
| 2009 | 329.54 Million MYR | -6.86% |
| 2008 | 353.83 Million MYR | 24.12% |
| 2007 | 285.07 Million MYR | 24.02% |
| 2006 | 229.86 Million MYR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 357.05 Million MYR | 10.95% |
| 2024 Q1 | 321.8 Million MYR | -16.8% |
| 2023 Q2 | 356.28 Million MYR | -1.33% |
| 2023 Q1 | 361.1 Million MYR | -15.87% |
| 2023 Q4 | 386.76 Million MYR | 12.23% |
| 2023 Q3 | 344.62 Million MYR | -3.27% |
| 2023 FY | 386.76 Million MYR | -9.89% |
| 2022 Q4 | 429.21 Million MYR | -11.69% |
| 2022 Q2 | 613.55 Million MYR | -19.9% |
| 2022 Q1 | 765.98 Million MYR | -24.86% |
| 2022 FY | 429.21 Million MYR | -57.9% |
| 2022 Q3 | 486.04 Million MYR | -20.78% |
| 2021 Q3 | 1.33 Billion MYR | -1.17% |
| 2021 Q4 | 1.01 Billion MYR | -23.63% |
| 2021 Q1 | 1.34 Billion MYR | 10.09% |
| 2021 FY | 1.01 Billion MYR | -16.49% |
| 2021 Q2 | 1.35 Billion MYR | 0.5% |
| 2020 Q3 | 1.23 Billion MYR | 19.44% |
| 2020 Q1 | 923.63 Million MYR | -0.28% |
| 2020 Q2 | 1.03 Billion MYR | 12.23% |
| 2020 Q4 | 1.22 Billion MYR | -1.4% |
| 2020 FY | 1.22 Billion MYR | 31.8% |
| 2019 FY | 926.23 Million MYR | 14.94% |
| 2019 Q4 | 926.23 Million MYR | 10.51% |
| 2019 Q1 | 806.75 Million MYR | 0.11% |
| 2019 Q2 | 820.84 Million MYR | 1.75% |
| 2019 Q3 | 838.18 Million MYR | 2.11% |
| 2018 Q4 | 805.85 Million MYR | 4.16% |
| 2018 Q3 | 773.67 Million MYR | 0.02% |
| 2018 Q1 | 670.51 Million MYR | -2.37% |
| 2018 FY | 805.85 Million MYR | 17.34% |
| 2018 Q2 | 773.51 Million MYR | 15.36% |
| 2017 Q1 | 528.92 Million MYR | 10.72% |
| 2017 FY | 686.79 Million MYR | 43.77% |
| 2017 Q4 | 686.79 Million MYR | 25.6% |
| 2017 Q3 | 546.81 Million MYR | 7.96% |
| 2017 Q2 | 506.48 Million MYR | -4.24% |
| 2016 Q1 | 444.14 Million MYR | -11.15% |
| 2016 FY | 477.7 Million MYR | -4.43% |
| 2016 Q2 | 510.67 Million MYR | 14.98% |
| 2016 Q3 | 439.49 Million MYR | -13.94% |
| 2016 Q4 | 477.7 Million MYR | 8.7% |
| 2015 Q2 | 425.28 Million MYR | 0.89% |
| 2015 Q3 | 461.26 Million MYR | 8.46% |
| 2015 Q4 | 499.84 Million MYR | 8.37% |
| 2015 FY | 499.84 Million MYR | 8.27% |
| 2015 Q1 | 421.52 Million MYR | -8.69% |
| 2014 Q4 | 461.65 Million MYR | 13.5% |
| 2014 Q1 | 392.95 Million MYR | 2.33% |
| 2014 Q3 | 406.72 Million MYR | 3.92% |
| 2014 Q2 | 391.38 Million MYR | -0.4% |
| 2014 FY | 461.65 Million MYR | 20.22% |
| 2013 Q1 | 363.56 Million MYR | -2.41% |
| 2013 FY | 384 Million MYR | 3.08% |
| 2013 Q4 | 384 Million MYR | 8.64% |
| 2013 Q3 | 353.47 Million MYR | -3.28% |
| 2013 Q2 | 365.44 Million MYR | 0.52% |
| 2012 Q3 | 327.42 Million MYR | 1.11% |
| 2012 FY | 372.54 Million MYR | 21.7% |
| 2012 Q2 | 323.83 Million MYR | 6.91% |
| 2012 Q4 | 372.54 Million MYR | 13.78% |
| 2012 Q1 | 302.9 Million MYR | 0.0% |
| 2011 FY | 306.11 Million MYR | -8.0% |
| 2010 FY | 332.72 Million MYR | 0.97% |
| 2009 FY | 329.54 Million MYR | -6.86% |
| 2008 FY | 353.83 Million MYR | 24.12% |
| 2007 FY | 285.07 Million MYR | 24.02% |
| 2006 FY | 229.86 Million MYR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| American Medical Technologies Inc. | 2.34 Million USD | -16359.305% |
| Ansell Limited | 1.32 Billion USD | 70.918% |
| Ansell Limited | 1.33 Billion USD | 70.972% |
| BG Medicine, Inc. | - USD | -Infinity% |
| Biotage AB (publ) | 126.33 Million USD | -206.138% |
| BioLife Sciences Inc. | - USD | -Infinity% |
| CB Scientific, Inc. | 943.17 Thousand USD | -40907.155% |
| Psykey, Inc. | 2.47 Million USD | -15533.186% |
| ConvaTec Group Plc | 2.01 Billion USD | 80.835% |
| ConvaTec Group Plc | 2.02 Billion USD | 80.863% |
| Encision Inc. | 1.98 Million USD | -19394.669% |
| Golden Valley Development, Inc | - USD | -Infinity% |
| Hear AtLast Holdings, Inc. | 3.04 Million USD | -12620.627% |
| Innovative MedTech Inc. | 6.13 Million USD | -6204.448% |
| LifePoint, Inc. | 2.45 Million USD | -15659.632% |
| Medite Cancer Diagnostics, Inc. | 10.18 Million USD | -3698.92% |
| Paradigm Medical Industries, Inc. | 3.4 Million USD | -11275.529% |
| QuantRx Biomedical Corporation | - USD | -Infinity% |
| Remedent, Inc. | 3.04 Million USD | -12621.28% |
| Reflect Scientific, Inc. | 776.32 Thousand USD | -49720.115% |
| SmileDirectClub, Inc. | 982.26 Million USD | 60.625% |
| Sector 10, Inc. | 9.84 Million USD | -3828.402% |
| Shandong Weigao Group Medical Polymer Company Limited | 1.35 Billion USD | 71.471% |
| SheerVision, Inc. | 1.43 Million USD | -26920.203% |
| United Health Products, Inc. | 1.99 Million USD | -19249.342% |
| Vasamed, Inc. | 1 Million USD | -38372.894% |
| Wearable Health Solutions, Inc. | 3.8 Million USD | -10077.342% |
| Yubo International Biotech Limited | 2.91 Million USD | -13173.098% |